# US 2015/0246112 A1 · Replicating recombinant adenovirus vectors, compositions, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0246112 A1
- Document ID: US20150246112A1
- Status: Published application
- Kind: A1
- Application number: 14/632,433
- Filed: 2015-02-26
- Published: 2015-09-03
- Earliest claimed: 2014-02-28
- Assignees: Beth Israel Deaconess Medical Center, Inc.; Crucell Holland B.V.
- Applicants: Beth Israel Deaconess Medical Center, Inc.; Crucell Holland B.V.
- Inventors: Dan BAROUCH; Peter ABBINK
- Web page: https://patentgrep.com/patent/US20150246112A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- C12N 2710/10052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2710/10143: viral genome or elements thereof as genetic vector
- C12N 2710/10171: Demonstrated in vivo effect
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/16143: viral genome or elements thereof as genetic vector
- C12N 2710/16171: Demonstrated in vivo effect
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.

## Claims

### Claim 1

A replicating recombinant adenovirus vector, comprising a recombinant adenovirus genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence;
(b) a functional E1 coding region;
(c) a deletion in the E3 coding region; and
(d) a deletion in the E4 coding region, provided that E4 open reading frame 6/7 is not deleted,
wherein the adenovirus genome is human adenovirus serotype 26 or 35 genome.

### Claim 2 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the heterologous nucleic acid sequence is located between left ITR and 5′-end of the functional E1 coding region

### Claim 3 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the heterologous nucleic acid sequence encodes an immunogenic polypeptide.

### Claim 4 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the heterologous nucleic acid sequence encodes an HIV antigen.

### Claim 5 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the heterologous nucleic acid sequence encodes a mosaic HIV antigen.

### Claim 6 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the heterologous nucleic acid sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO 48 or SEQ ID NO 50

### Claim 7 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the vector is lyophilized.

### Claim 8 (depends on 1)

The replicating recombinant adenovirus vector of claim 1, wherein the replicative capacity of the vector is attenuated by at least about 80-fold, as compared to the replicative capacity of a wild-type human adenovirus serotype 26 or 35, respectively.

### Claim 9

A replicating recombinant adenovirus vector comprising a recombinant human adenovirus serotype 26 genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 48 or SEQ ID NO 50;
(b) a functional E1 coding region encoding the amino acid sequences of SEQ ID NOs: 14-16;
(c) a partially deleted E3 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO 6; and
(d) a partially deleted E4 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO 22.

### Claim 10 (depends on 9)

The replicating recombinant adenovirus vector of claim 9, wherein the heterologous nucleic acid sequence is located between left ITR and 5′-end of the functional E1 coding region.

### Claim 11 (depends on 10)

The replicating recombinant adenovirus vector of claim 10, wherein,
a. the promoter is CMV promoter having the nucleotide sequence of SEQ ID NO: 51, and the heterologous nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO 47 or SEQ ID NO 49;
b. the functional E1 coding region comprises the nucleotide sequence of SEQ ID NO 13;
c. the partially deleted E3 coding region consists of the nucleotide sequence of SEQ ID NO: 5; and
d. the partially deleted E4 coding region consists of the nucleotide sequence of SEQ ID NO: 23.

### Claim 12 (depends on 1)

A composition comprising the replicating recombinant adenovirus vector of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12 being formulated for oral administration to a subject.

### Claim 14 (depends on 13)

The composition of claim 13, being an enteric-coated capsule.

### Claim 15 (depends on 1)

A method of producing a replicating adenovirus particle, comprising:
introducing the replicating recombinant adenovirus vector of claim 1 into a cell under conditions sufficient for replication of the recombinant adenovirus genome and packaging of the adenovirus particle in the cell; and
collecting the adenovirus particle.

### Claim 16 (depends on 12)

A method of producing an immune response in a subject, comprising: administering to the subject an immunogenically effective amount of the composition according to claim 12.

### Claim 17 (depends on 16)

The method of claim 16, wherein the composition is orally administered to the subject.

### Claim 18 (depends on 12)

A method of vaccinating a subject against an infection, comprising: administering to the subject an immunogenically effective amount of a composition according to claim 12.

### Claim 19

A method of vaccinating a human subject against an HIV infection, comprising: orally administering to the subject an immunogenically effective amount of a composition comprising a pharmaceutically acceptable carrier and a replicating recombinant adenovirus vector comprising a recombinant serotype 26 adenovirus genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence encoding the ammo acid sequence of SEQ ID NO: 48 or SEQ ID NO: 50;
(b) a functional E1 coding region encoding the amino acid sequences of SEQ ID NOs: 14-16;
(c) a partially deleted E3 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO 6; and
(d) a partially deleted E4 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO 22,
wherein the heterologous nucleic acid sequence is located between left ITR and 5′-end of the functional E1 coding region.

### Claim 20 (depends on 19)

The method of claim 19, wherein
a. the promoter is CMV promoter having the nucleotide sequence of SEQ ID NO 51 and the heterologous nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:′47 or SEQ ID NO: 49;
b. the functional E1 coding region comprises the nucleotide sequence of SEQ ID NO: 13;
c. the partially deleted E3 coding region consists of the nucleotide sequence of SEQ ID NO: 5; and
d. the partially deleted E4 coding region consists of the nucleotide sequence of SEQ ID NO: 23.

### Claim 21

(canceled)
